Latest & greatest articles for atrial fibrillation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atrial fibrillation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atrial fibrillation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atrial fibrillation

101. Ablation of Atrial Fibrillation Drivers

Ablation of Atrial Fibrillation Drivers 195 © RADCLIFFE CARDIOLOGY 2017 Access at: www.AERjournal.com Diagnostic Electrophysiology and Ablation Treatment of atrial fibrillation (AF) classically focuses on eliminating triggers near and from the pulmonary veins, which may initiate AF. However, the 1–2 year success rate of pulmonary vein isolation (PVI) remains 40–50 % for persistent AF 1,2 and 50–65 % for paroxysmal AF, 3–5 while supplementary linear lesions or extensive ablation at electrogram (...) -targets have had disappointing results and may not improve the success of pulmonary vein isolation. 1,2,6 In recent years, focal or rotational drivers for AF have gained increasing attention as ablation targets. This approach is now supported by wide evidence ranging from optical mapping of animal and human AF 7,8 (Figure 1) to several multicentre non-randomised clinical trials of AF driver ablation, yet the paucity of randomised trials in this area still remains a shortcoming. 9–14 In this review, we

Arrhythmia & electrophysiology review2017 Full Text: Link to full Text with Trip Pro

102. PulmOnary vein isolation With vs. without continued antiarrhythmic Drug trEatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from a multicentre randomized trial

PulmOnary vein isolation With vs. without continued antiarrhythmic Drug trEatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from a multicentre randomized trial 29211857 2017 12 06 1522-9645 2017 Dec 02 European heart journal Eur. Heart J. PulmOnary vein isolation With vs. without continued antiarrhythmic Drug trEatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from a multicentre randomized trial. 10.1093/eurheartj/ehx666 Catheter ablation (...) is indicated in patients with symptomatic paroxysmal atrial fibrillation (AF) resistant to antiarrhythmic drug therapy (ADT). We investigated whether continued use of previously ineffective ADT beyond the post-ablation blanking period reduces recurrence of atrial tachyarrhythmia within the 1st year after ablation. This was a multicentre, randomized controlled study in patients undergoing contact force-guided pulmonary vein isolation (PVI) for paroxysmal AF in whom previously ineffective ADT was continued

EvidenceUpdates2017

103. Quality of life improves after thoracoscopic surgical ablation of advanced atrial fibrillation: Results of the Atrial Fibrillation Ablation and Autonomic Modulation via Thoracoscopic Surgery (AFACT) study

Quality of life improves after thoracoscopic surgical ablation of advanced atrial fibrillation: Results of the Atrial Fibrillation Ablation and Autonomic Modulation via Thoracoscopic Surgery (AFACT) study 29089093 2017 11 01 1097-685X 2017 Sep 27 The Journal of thoracic and cardiovascular surgery J. Thorac. Cardiovasc. Surg. Quality of life improves after thoracoscopic surgical ablation of advanced atrial fibrillation: Results of the Atrial Fibrillation Ablation and Autonomic Modulation via (...) Thoracoscopic Surgery (AFACT) study. S0022-5223(17)32134-7 10.1016/j.jtcvs.2017.09.093 We evaluated health-related quality of life at 12 months after thoracoscopic surgical ablation in patients enrolled in the Atrial Fibrillation Ablation and Autonomic Modulation via Thoracoscopic Surgery study. The Atrial Fibrillation Ablation and Autonomic Modulation via Thoracoscopic Surgery study assessed the efficacy and safety of ganglion plexus ablation in patients with symptomatic advanced atrial fibrillation

EvidenceUpdates2017

104. Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation

Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation 29169468 2017 12 04 2017 12 04 1558-3597 70 21 2017 Nov 28 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation. 2621-2632 S0735-1097(17)40979-X 10.1016/j.jacc.2017.09.1087 Lifelong oral anticoagulation, either with warfarin or a non-vitamin K antagonist oral anticoagulant (NOAC), is indicated for stroke prevention in most patients (...) with atrial fibrillation (AF). Emerging evidence suggests that NOACs may be associated with better renal outcomes than warfarin. This study aimed to compare 4 oral anticoagulant agents (apixaban, dabigatran, rivaroxaban, and warfarin) for their effects on 4 renal outcomes: ≥30% decline in estimated glomerular filtration rate (eGFR), doubling of the serum creatinine level, acute kidney injury (AKI), and kidney failure. Using a large U.S. administrative database linked to laboratory results, the authors identified 9,769

EvidenceUpdates2017

105. Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation

Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation 29111209 2017 11 27 2017 11 28 1879-1913 120 12 2017 Dec 15 The American journal of cardiology Am. J. Cardiol. Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation. 2176-2181 S0002-9149(17)31459-5 10.1016/j.amjcard.2017.09.003 We investigated the incidence of nonembolic adverse events in 2 cohorts of patients (...) with atrial fibrillation (AF) and validated the 2MACE score ([metabolic syndrome, age ≥75] [doubled]; [myocardial infarction or revascularization, congestive heart failure {HF}, and stroke, transient ischemic attack or thromboembolism]) as predictor of major adverse cardiovascular events (MACEs). We recruited 2,630 patients with AF from 2 different cohorts (Murcia AF and FANTASIIA). The 2MACE score was calculated, and during a median of 7.2 years (Murcia AF cohort) and 1.01 years (FANTASIIA) of follow-up, we recorded

EvidenceUpdates2017

106. CHA2DS2-VASc Score for Identifying Truly Low-Risk Atrial Fibrillation for Stroke: A Korean Nationwide Cohort Study

CHA2DS2-VASc Score for Identifying Truly Low-Risk Atrial Fibrillation for Stroke: A Korean Nationwide Cohort Study 28939672 2017 10 26 2017 10 26 1524-4628 48 11 2017 Nov Stroke Stroke CHA2DS2-VASc Score for Identifying Truly Low-Risk Atrial Fibrillation for Stroke: A Korean Nationwide Cohort Study. 2984-2990 10.1161/STROKEAHA.117.018551 As the threshold of stroke risk for initiating oral anticoagulants is lowered after the introduction of the nonvitamin K antagonist oral anticoagulants (...) , the focus of stroke prevention in patients with nonvalvular atrial fibrillation has shifted away from predicting high-risk patients toward initially identifying patients with a truly low risk of ischemic stroke, who do not need antithrombotic therapy. We tested the predictive ability of the congestive heart failure, hypertension, age ≥75, diabetes mellitus, prior stroke or transient ischemic attack (doubled; CHADS2), congestive heart failure, hypertension, age ≥75 (doubled), diabetes mellitus, prior

EvidenceUpdates2017

107. Implantable loop recorders for diagnosis of atrial fibrillation in cryptogenic stroke

Implantable loop recorders for diagnosis of atrial fibrillation in cryptogenic stroke 1 Public Summary Document Application No. 1443 – Implantable loop recorders for diagnosis of atrial fibrillation in cryptogenic stroke Applicant: Medtronic Australasia Pty Ltd Date of MSAC consideration: MSAC 69 th Meeting, 6-7 April 2017 Context for decision: MSAC makes its advice in accordance with its Terms of Reference, visit the MSAC website 1. Purpose of application An application requesting Medicare (...) Benefits Schedule (MBS) listing for the insertion of implantable loop recorders (ILR), and an investigation service of the inserted ILR, for the diagnosis of atrial fibrillation (AF) in patients with cryptogenic stroke or embolic stroke of undetermined source (CS/ESUS) was received from Medtronic Australasia Pty Ltd by the Department of Health (the Department). 2. MSAC’s advice to the Minister After considering the strength of the available evidence in relation to the comparative safety, clinical

Medical Services Advisory Committee2017

109. Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort Study.

Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort Study. Background: Dabigatran (150 mg twice daily) has been associated with lower rates of stroke than warfarin in trials of atrial fibrillation, but large-scale evaluations in clinical practice are limited. Objective: To compare incidence of stroke, bleeding, and myocardial infarction in patients receiving dabigatran versus warfarin in practice. Design: Retrospective cohort. Setting (...) : National U.S. Food and Drug Administration Sentinel network. Patients: Adults with atrial fibrillation initiating dabigatran or warfarin therapy between November 2010 and May 2014. Measurements: Ischemic stroke, intracranial hemorrhage, extracranial bleeding, and myocardial infarction identified from hospital claims among propensity score-matched patients starting treatment with dabigatran or warfarin. Results: Among 25 289 patients starting dabigatran therapy and 25 289 propensity score-matched

Annals of Internal Medicine2017

110. Association of of Atrial Fibrillation Clinical Phenotypes With Treatment Patterns and Outcomes: A Multicenter Registry Study

Association of of Atrial Fibrillation Clinical Phenotypes With Treatment Patterns and Outcomes: A Multicenter Registry Study 29128866 2018 11 13 2380-6591 3 1 2018 Jan 01 JAMA cardiology JAMA Cardiol Association of of Atrial Fibrillation Clinical Phenotypes With Treatment Patterns and Outcomes: A Multicenter Registry Study. 54-63 10.1001/jamacardio.2017.4665 Atrial fibrillation (AF) is usually classified on the basis of the disease subtype. However, this characterization does not capture (...) the full heterogeneity of AF, and a data-driven cluster analysis reveals different possible classifications of patients. To characterize patients with AF based on a cluster analysis and to evaluate the association between these phenotypes, treatment, and clinical outcomes. This cluster analysis used data from an observational cohort that included 9749 patients with AF who had been admitted to 174 US sites participating in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT

JAMA cardiology2017 Full Text: Link to full Text with Trip Pro

111. Sex Differences and Similarities in Atrial Fibrillation Epidemiology, Risk Factors, and Mortality in Community Cohorts: Results From the BiomarCaRE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe)

Sex Differences and Similarities in Atrial Fibrillation Epidemiology, Risk Factors, and Mortality in Community Cohorts: Results From the BiomarCaRE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe) 29038167 2017 10 17 2017 10 27 2017 10 27 1524-4539 136 17 2017 Oct 24 Circulation Circulation Sex Differences and Similarities in Atrial Fibrillation Epidemiology, Risk Factors, and Mortality in Community Cohorts: Results From the BiomarCaRE Consortium (Biomarker for Cardiovascular (...) Risk Assessment in Europe). 1588-1597 10.1161/CIRCULATIONAHA.117.028981 Atrial fibrillation (AF) is a common cardiac disease in aging populations with high comorbidity and mortality. Sex differences in AF epidemiology are insufficiently understood. In N=79 793 individuals without AF diagnosis at baseline (median age, 49.6 years; age range, 24.1-97.6 years; 51.7% women) from 4 community-based European studies (FINRISK, DanMONICA, Moli-sani Northern Sweden) of the BiomarCaRE consortium (Biomarker

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro

112. Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction: The CAMERA-MRI Study

Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction: The CAMERA-MRI Study 28855115 2017 08 31 2017 10 19 2017 10 19 1558-3597 70 16 2017 Oct 17 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction: The CAMERA-MRI Study. 1949-1961 S0735-1097(17)39349-X 10.1016/j.jacc.2017.08.041 Atrial fibrillation (AF) and left ventricular systolic dysfunction (...) (LVSD) frequently co-exist despite adequate rate control. Existing randomized studies of AF and LVSD of varying etiologies have reported modest benefits with a rhythm control strategy. The goal of this study was to determine whether catheter ablation (CA) for AF could improve LVSD compared with medical rate control (MRC) where the etiology of the LVSD was unexplained, apart from the presence of AF. This multicenter, randomized clinical trial enrolled patients with persistent AF and idiopathic

EvidenceUpdates2017

113. Usefulness of CHADS2 and CHA2DS2-VASc Scores for Stroke Prediction in Patients With Cancer and Atrial Fibrillation

Usefulness of CHADS2 and CHA2DS2-VASc Scores for Stroke Prediction in Patients With Cancer and Atrial Fibrillation 29033049 2017 10 16 2017 10 16 1879-1913 2017 Sep 20 The American journal of cardiology Am. J. Cardiol. Usefulness of CHADS2 and CHA2DS2-VASc Scores for Stroke Prediction in Patients With Cancer and Atrial Fibrillation. S0002-9149(17)31457-1 10.1016/j.amjcard.2017.08.038 Stroke prediction scores have not been validated in patients with cancer and atrial fibrillation (AF). We aimed (...) to identify unique risk factors and evaluate validity of CHADS2 and CHA2DS2-VASc scores to predict risk of stroke and mortality. A retrospective review of all patients with cancer with pre-existing AF presenting from 2008 to 2014 was performed. Outcomes included ischemic stroke and mortality. Prognostic factors were identified with Fine and Gray regression for stroke and Cox proportional hazards analysis for survival. After excluding patients with hemorrhagic strokes, 2,037 patients were analyzed

EvidenceUpdates2017

114. The Association of Gamma-Glutamyl Transferase and Atrial Fibrillation

The Association of Gamma-Glutamyl Transferase and Atrial Fibrillation "The Association of Gamma-Glutamyl Transferase and Atrial Fibrillation" by Lauren K. Riley < > > > > > Title Author Date of Graduation Summer 9-30-2017 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Atrial fibrillation (AF) is the most commonly diagnosed cardiac arrhythmia in clinical practice and is related to significant morbidity and mortality. AF (...) etiology and thus, predictive biomarkers are currently lacking. Liver enzymes have shown a correlation to cardiovascular disease. Gamma-glutamyl transferase (GGT) is a liver enzyme associated with oxidative stress that is postulated to have a link to AF occurrence. Researchers have recently placed emphasis on discovering a potential biomarker to predict AF. An elevation of systemic serum GGT and the association with the risk of AF development is the area of interest. Methods: Exhaustive search

Pacific University EBM Capstone Project2017

115. Incidence of Previously Undiagnosed Atrial Fibrillation Using Insertable Cardiac Monitors in a High-Risk Population: The REVEAL AF Study

Incidence of Previously Undiagnosed Atrial Fibrillation Using Insertable Cardiac Monitors in a High-Risk Population: The REVEAL AF Study 28842973 2018 11 13 2380-6591 2 10 2017 Oct 01 JAMA cardiology JAMA Cardiol Incidence of Previously Undiagnosed Atrial Fibrillation Using Insertable Cardiac Monitors in a High-Risk Population: The REVEAL AF Study. 1120-1127 10.1001/jamacardio.2017.3180 In approximately 20% of atrial fibrillation (AF)-related ischemic strokes, stroke is the first clinical (...) manifestation of AF. Strategies are needed to identify and therapeutically address previously undetected AF. To quantify the incidence of AF in patients at high risk for but without previously known AF using an insertable cardiac monitor. This prospective, single-arm, multicenter study was conducted from November 2012 to January 2017. Visits took place at 57 centers in the United States and Europe. Patients with a CHADS2 score of 3 or greater (or 2 with at least 1 additional risk factor) were enrolled

JAMA cardiology2017 Full Text: Link to full Text with Trip Pro

116. Global longitudinal strain corrected by RR interval is a superior predictor of all‐cause mortality in patients with systolic heart failure and atrial fibrillation

Global longitudinal strain corrected by RR interval is a superior predictor of all‐cause mortality in patients with systolic heart failure and atrial fibrillation 29024533 2018 11 13 2055-5822 5 2 2018 04 ESC heart failure ESC Heart Fail Global longitudinal strain corrected by RR interval is a superior predictor of all-cause mortality in patients with systolic heart failure and atrial fibrillation. 311-318 10.1002/ehf2.12220 Quantification of systolic function in patients (...) with atrial fibrillation (AF) is challenging. A novel approach, based on RR interval correction, to counteract the varying heart cycle lengths in AF has recently been proposed. Whether this method is superior in patients with systolic heart failure (HFrEF) with AF remains unknown. This study investigates the prognostic value of RR interval-corrected peak global longitudinal strain {GLSc = GLS/[RR^(1/2)]} in relation to all-cause mortality in HFrEF patients displaying AF during echocardiographic examination

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

117. Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation.

Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation. Importance: Non-vitamin K oral anticoagulants (NOACs) are commonly prescribed with other medications that share metabolic pathways that may increase major bleeding risk. Objective: To assess the association between use of NOACs with and without concurrent medications and risk of major bleeding in patients with nonvalvular (...) atrial fibrillation. Design, Setting, and Participants: Retrospective cohort study using data from the Taiwan National Health Insurance database and including 91 330 patients with nonvalvular atrial fibrillation who received at least 1 NOAC prescription of dabigatran, rivaroxaban, or apixaban from January 1, 2012, through December 31, 2016, with final follow-up on December 31, 2016. Exposures: NOAC with or without concurrent use of atorvastatin; digoxin; verapamil; diltiazem; amiodarone; fluconazole; ketoconazole

JAMA2017 Full Text: Link to full Text with Trip Pro

118. Implantable cardiac loop recorders for detection of atrial fibrillation following cryptogenic stroke

Implantable cardiac loop recorders for detection of atrial fibrillation following cryptogenic stroke Implantable cardiac loop recorders for detection of atrial fibrillation following cryptogenic stroke Implantable cardiac loop recorders for detection of atrial fibrillation following cryptogenic stroke HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) HAYES, Inc. Implantable cardiac loop recorders for detection of atrial fibrillation following cryptogenic stroke. Lansdale: HAYES, Inc. Healthcare Technology Brief Publication. 2017 Authors' conclusions Approximately one-third of strokes are cryptogenic (lack an identifiable and treatable cause). Undetected atrial fibrillation (AF) is one suspected cause of cryptogenic stroke. Inability to detect suspected AF after cryptogenic stroke presents a clinical management dilemma. Description of Technology

Health Technology Assessment (HTA) Database.2017

119. Left ventricular torsional parameters before and after atrial fibrillation ablation: a velocity vector imaging study

Left ventricular torsional parameters before and after atrial fibrillation ablation: a velocity vector imaging study 29038727 2018 11 13 2008-5842 9 9 2017 Sep Electronic physician Electron Physician Left ventricular torsional parameters before and after atrial fibrillation ablation: a velocity vector imaging study. 5395-5401 10.19082/5395 Effects of atrial fibrillation (AF) and its ablative treatment on LV torsion have not yet been fully investigated. This study aimed to examine whether AF (...) patterns of LV contraction and its ablative correction can exert a significant impact on LV torsion by velocity vector imaging (VVI). This case-control study conducted in Rajaie Cardiovascular, Medical and Research Center between October 2012 and June 2013. Study participants were 30 consecutive patients with symptomatic paroxysmal AF who met the inclusion criteria. The control group included 24 healthy participants with no history of cardiovascular disease. All individuals were in sinus rhythm

Electronic physician2017 Full Text: Link to full Text with Trip Pro

120. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib

Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib 29296820 2018 11 13 2473-9529 1 20 2017 Sep 12 Blood advances Blood Adv Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. 1739-1748 10.1182/bloodadvances.2017009720 Atrial fibrillation (AF) has been reported in up to 16% of patients taking ibrutinib. Data regarding the management of AF in this patient population are limited (...) , and stroke prevention poses a challenge because of increased risk of bleeding with ibrutinib treatment. Our study sought to describe the incidence of AF in adult patients treated with ibrutinib for a hematologic malignancy, assess management strategies, evaluate stroke and bleeding outcomes, and identify risk factors for occurrence. Of 582 patients treated with ibrutinib, 76 developed AF. With a median follow-up of 32 months, the estimated cumulative incidence at 6 months, 1 year, and 2 years was 5.9

Blood advances2017 Full Text: Link to full Text with Trip Pro